

Gene Section

Short Communication

KDR (kinase insert domain receptor)/Vascular Endothelial Growth Factor Receptor 2 (VEGFR2)

Noah Sorrelle, Rolf Brekken

University of Texas Southwestern Medical Center noah.sorrelle@utsouthwestern.edu,
rolf.brekken@utsouthwestern.edu

Published in Atlas Database: October 2015

Online updated version : <http://AtlasGeneticsOncology.org/Genes/KDRID41055ch4q12.html>

Printable original version : <http://documents.irevues.inist.fr/bitstream/handle/2042/66055/10-2015-KDRID41055ch4q12.pdf>

DOI: 10.4267/2042/66055

This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 2.0 France Licence.
© 2016 Atlas of Genetics and Cytogenetics in Oncology and Haematology

Abstract

This is a concise review of the KDR/VEGFR2 gene, including expression, function, and implications of VEGFR2 expression in cancer.

Keywords

CD309, Kdr, Flk-1, VEGFR2, Angiogenesis, Vascular Endothelial Growth Factor Receptor 2, Tumor Angiogenesis

Identity

Other names: CD309, Flk1, VEGFR, VEGFR2

HGNC (Hugo): KDR

Location: 4q12

DNA/RNA

Description

The human KDR/VEGFR2 gene was cloned in 1991 and mapped in 1992 (Terman BI et al., 1991, Terman BI et al., 1992). The human gene (Kdr/VEGFR2) maps to human chromosome 4. The mouse gene (Kdr/Vegfr2/Flk-1) was cloned in 1991 (Matthews W et al., 1991). The mouse gene (Flk-1/Vegfr2) is located on mouse chromosome 5.

Transcription

In humans, the KDR gene consists of 30 exons, spanning 47,337 bp of DNA on the reverse strand of Chromosome 4. Exon 1 contains 5' UTR and exon 30 contains 3' UTR. All 30 exons contain translated

sequence. Three splice variants have been reported in Ensembl. Alternative splicing results in partial retention of intron 13 and an alternative stop codon, encoding a unique C-terminal sequence. Transcription factors regulating Vegfr2 expressing include ETS1 and ETS2 (Elvert G et al., 2003, Kappel A et al., 2000), EPAS1 (hypoxia inducible factor 2 alpha) (Elvert G et al., 2003), ETV2 (ER71/etsrp) (Lee D et al., 2008), and OVOL2 (Kim JY et al., 2014).


Protein

Description

The canonical form of VEGFR2 comprises 1356 amino acids in humans and 1345 in mice. VEGFR2 is translated into a 150 kDa protein. Glycosylation of the extracellular domain results in the mature form at the cell surface which migrates at 230 kDa via western blot.

VEGFR2 is composed of three domains: an extracellular domain, transmembrane domain, and a cytosolic domain. The extracellular domain (including N-terminus) is composed of a signal peptide (aa: 1-20) and seven Ig-like subdomains (aa: 20-764).

The second and third Ig-like subdomains (aa: 141-207, 224-320) facilitate binding of the principal VEGFR2 ligand, VEGFA (Fug G et al., 1998, Shinkai A et al., 1998). This is followed by a single-pass type I transmembrane domain (aa: 765-785).



The intracellular region (aa: 786-1356) consists of a juxtamembrane domain (JMD) and kinase domain. Biochemical analyses by Solowiej et al. (2009) determined that the JMD promotes autophosphorylation of the kinase domain, which is preceded by phosphorylation of the JMD residue, Y801(Solowiej J et al., 2009).

Replacing the VEGFR2 JMD with the VEGFR1 JMD reduces the kinase activity of VEGFR2 in vitro. Conversely, replacing the VEGFR1 JMD with the VEGFR2 JMD increases the kinase activity of VEGFR1(Gille H et al., 2000).

These data suggest that the higher kinase activity of VEGFR2 relative to VEGFR1 may be partially explained by differences in the JMD.

The kinase domain (KD; aa: 834-1162) is split by a 70 amino acid insert (aa: 930-1000).

Phosphorylation of the KD activation loop residues Y1054 and Y1059 is required for kinase activity(Kendall RL et al., 1999).

Additional phosphorylation sites in the intracellular domain facilitate specific interactions of between VEGFR2 and signaling mediators, including PLC gamma, SHB, SCK, SHCA, GRB2, son of sevenless (SOS), and NCK. For further review, see S. Koch and L. Claesson-Welsh, 2012, and Claesson-Welsh and Welsh, 2013 (Claesson-Welsh L et al., 2013, Koch S et al., 2012).

Co-receptors:

Integrins, neuropilin-1, and CD146 promote VEGFR2 activation, and mediate VEGFR2 activities, including endothelial cell migration, permeability, and angiogenesis.

For more information, see Table 1 and Koch and Claesson-Welsh, 2012.




Figure 1: Annotated VEGFR2 Protein. The figure was constructed using Geneious v8.0, (<http://www.geneious.com>).

Table 1: VEGFR2 Co-receptors

Co-receptor	Association and Function with VEGFR2	Reference(s)
CD146	Interacts with directly with VEGFR2 upon Nrp1-binding of VEGF-A	Jiang et al., 2012
	Mediates endothelial cell migration and microvascular formation	
	Mediates VEGFR2-dependent tumor angiogenesis	
Neuropilin-1	Mediates VEGFR2-dependent permeability	Becker et al., 2005
	Binds VEGF-A, allowing formation of a VEGFR2/Nrp-1 complex that increases VEGF-A affinity for VEGFR2	Soker et al. 1998, 2002
	Mediates endothelial cell migration	Wang et al., 2003
	Nrp1 knockout mice die at E14 and display severe vascular and nervous system defects	Kawasaki et al, 1999; Gu et al., 2003
alpha V beta 3 Integrin	Mediates in VEGFR2-dependent tumor angiogenesis	Mahabeleshwar et al., 2006
	Binds VEGFR2 through its extracellular domain	Borges et al. 2000; Liu et al. 2009
	May be required for full VEGF-dependent phosphorylation of VEGFR2 and angiogenesis	Masson-Gadais et al., 2003; Mahabeleshwar et al., 2008

Table 2: Effect of VEGFR2 signalling by cell type

Cell Type	Function of VEGFR2	Reference(s)
B cells	Selective ligation of VEGFR2 in vivo reduces bone marrow pro-B cells and splenic B cells	Huang et al., 2007
Endothelial cells	Promotes survival, proliferation, and migration	Terman et al., 1992a; Waltenberger et al., 1994; Gerber et al., 1998; Jia et al., 2004
Hemangioblasts	Development of hemangioblasts	Shalaby et al., 1995
Myeloid-Derived Suppressor Cells	Promotes MDSC expansion in spleen, which is associated with splenomegaly	Huang et al., 2007
	chemotaxis	Dineen et al., 2008; Roland et al., 2009
Hematopoietic stem cells	Functions in the generation and survival of HSCs	Larrivée et al., 2003
T cells	Selective ligation of VEGFR2 in vivo inhibits thymic T cell differentiation, results in thymic atrophy, and reduces splenic T cells.	Huang et al., 2007
Dendritic cells	VEGF inhibits splenic dendritic cells and dendritic cell maturation through activation of VEGFR2	Gabrilovich et al., 1996, 1998, 1999
	VEGFR2 activation inhibits dendritic cell-driven allogeneic T-cell proliferation in vitro	Huang et al., 2007
	Dendritic cell-specific deletion of VEGFR2 diminishes the type I interferon response in plasmacytoid dendritic cells	Agudo et al., 2014

Alternative Isoforms:

In 2009, Albuquerque et al. discovered that alternative splicing produces a soluble form of VEGFR2, present in mouse and human cornea (Albuquerque RJ et al., 2009). This isoform results from inclusion of the intron following exon 13 and results in a truncated product which migrates at 75 kDa via western blot. This isoform contains only the extracellular domain of VEGFR2 and a unique C-terminal sequence. Characterization of sVEGFR2 revealed that it may play a role as an endogenous inhibitor of lymphoangiogenesis via antagonizing VEGF-C/VEGFR3 signaling (Albuquerque RJ et al., 2009).

Ligands:

VEGF-A (Terman BI et al., 1992), VEGF-C (Joukov V et al., 1996), VEGF-D (Achen MG et al., 1998), and VEGF-E (M Meyer et al., 1999, Ogawa S et al., 1998). VEGF-A is the primary endogenous ligand activating VEGFR2 signaling, while VEGF-C and

VEGF-D signal mostly through VEGFR3. VEGF-E is encoded by the Orf virus and activates VEGFR2 similarly to VEGF-A. Unlike VEGF-A, however, VEGF-E is a VEGFR2-exclusive ligand.

Expression

VEGFR2 is the principal VEGF receptor expressed on blood endothelial cells. Vegfr2-null mice die at E8.5 due to inadequate development of endothelial and hematopoietic cells (Shalaby F et al., 1995). Vegfr2 expression levels peak during embryonic angiogenesis and vasculogenesis (Millauer B et al., 1993, Oelrichs RB et al., 1993). In adults, VEGFR2 is expressed prominently on vascular endothelial cells, where its expression is, in part, regulated by fibroblast growth factor signaling (Michael S. Pepper et al., 1998, Murakami M et al., 2011). Expression is also observed on hematopoietic stem cells and megakaryocytes (Casella I et al., 2003, Katoh O et al., 1995, Larrivé B et al., 2003).

Table 3: VEGF Family Inhibitors: Recombinant Protein and Monoclonal Antibodies

Drug	Type	Target	Mechanism of Inhibition	Clinical Status
bevacizumab (Avastin)	Humanized monoclonal antibody	Human VEGF-A	Prevents VEGF-A from binding VEGFR1 or VEGFR2	Approved for cervical, colorectal, glioblastoma, NSCLC, ovarian, and renal cell cancer
2C3	Mouse monoclonal antibody	Human VEGF-A	Specifically prevents VEGF-A from binding VEGFR2	Useful tool for preclinical studies to specifically block VEGF-A produced by human cancer cells
r84	Human monoclonal antibody	Human, Mouse VEGF-A	Specifically prevents VEGF-A from binding VEGFR2	Effective in preclinical studies; candidate for clinical trial
mcr84	Mouse chimeric monoclonal antibody	Human, Mouse VEGF-A	Specifically prevents VEGF-A from binding VEGFR2	Useful tool for preclinical studies in immunocompetent murine models of cancer
afibercept (VEGF-Trap)	Recombinant protein consisting of human VEGFR1 and VEGFR2 extracellular domains fused to human IgG1 FC domain	VEGFR1 and VEGFR2 ligands	Acts as a decoy for VEGFR1 and VEGFR2 ligands	Approved for treatment of wet macular degeneration and metastatic colorectal cancer
icrucumab (IMC-18F1)	Human monoclonal antibody	Human VEGFR1	Blocks ligand-dependent signalling	In Phase II for Breast Cancer (AUG2015)
DC101	Rat monoclonal antibody	Mouse VEGFR2	Blocks ligand-dependent signalling	Useful tool for preclinical studies
ramucirumab (IMC-1121B)	Human monoclonal antibody	Human VEGFR2	Blocks ligand-dependent signalling	Approved for gastric adenocarcinoma, metastatic NSCLC, and metastatic colorectal cancer

Table 4: Small Molecule Inhibitors of VEGF Receptors

Drug	Specificity	Targets	Mechanism of Inhibition	Clinical Status
sorafenib	Multi-RTK Inhibitor	KIT, Flt3, PDGFR-B, VEGFR2, VEGFR3, Raf kinases	ATP-binding site competitive inhibitor	Approved for advanced renal cell carcinoma, hepatocellular carcinoma, and thyroid cancer
pazopanib	Multi-RTK Inhibitor	FGFR1, VEGFR1-3, PDGFR, KIT, c-Fms	ATP-binding site competitive inhibitor	Approved for advanced renal cell carcinoma and soft tissue sarcoma
sunitinib	Multi-RTK Inhibitor	PDGF-Rs, VEGFR1-3, KIT, RET, CSF-1R, Flt3	ATP-binding site competitive inhibitor	Approved for renal cell carcinoma, gastrointestinal stromal tumors, and well-differentiated pancreatic neuroendocrine tumors
nintedanib	Multi-RTK Inhibitor	VEGFR1-3PDGFRa and B, FGFR1-3	ATP-binding site competitive inhibitor	Approved for idiopathic pulmonary fibrosis. Approved for NSCLC in the EU. Clinical trials ongoing for a variety of solid tumors.
apatinib	Exhibits higher selectivity for VEGFR2	VEGFR2, RET; lesser activity on cKIT, c-Src	ATP-binding site competitive inhibitor	Clinical trials ongoing for a variety of solid tumors; approved for late stage gastric cancer in China

Table 5: VEGFR2 point mutations and associated phenotype

Mutation	Amino Acid Change	Codon #	Affected Domain	Phenotype	Reference(s)
GTA -> ATA	Val-Ile	297	Ig-Like Domain 3	Associated with coronary heart disease	Wang et al., 2007
CAT -> CAA	His-Gln	472	Ig-Like Domain 5	Associated with coronary heart disease	Wang et al., 2007
TGT -> CGT	Cys-Arg	482	Ig-Like Domain 5	Associated with Hemangioma; affects VEGFR2's ability to regulate VEGFR1 expression	Jinnin et al., 2008
CCC -> TCC	Pro-Ser	1147	Kinase Domain	Associated with Hemangioma	Walter et al., 2002
Unreported	Asp-Val	717	Ig-Like Domain 7	Identified in angiosarcoma; results in ligand-independent activation of VEGFR2	Antonescu et al., 2009
Unreported	Thr-Arg	771	Transmembrane Domain	Identified in angiosarcoma	Antonescu et al., 2009
Unreported	Ala-Thr	1065	Kinase Domain	Identified in angiosarcoma; results in ligand-independent activation of VEGFR2	Antonescu et al., 2009

Table 6: Characterized VEGFR2 Single Nucleotide Polymorphisms (SNP)

SNP Position	Chromosome 4 Position	Sequence	Phenotype
-2854	55835242	tacatgcagt(A-C)actccttaa	(-2854C) Increased VEGFR2 expression in vitro; correlates with increased VEGFR2 mRNA in patient tumors
-2766	55835154	gtaagtgggt(A-T)aatgacacac	(-2766T) No change in vitro; correlates with increased VEGFR2 mRNA in patient tumors
-2455	55834843	gaatgtggta (G-A)actgattca	(-2455A) Increased VEGFR2 expression in vitro; correlates with increased VEGFR2 mRNA in patient tumors
-906	55833294	agcgggaatg(T-C)tgccgaactg	(-906C) Increased VEGFR2 expression in vitro; correlates with increased VEGFR2 mRNA in patient tumors
-271	55832659	agagcgggtca(G-A)tgtgtggtcg	(-271A) Reduced VEGFR2 expression in vitro; correlates with decreased VEGFR2 protein in patient tumors
18487	55813902	cttatagcca(A-T)gctgtctcag	(18487T) Q472H; Increased VEGF-A binding and VEGF-A-dependent VEGFR2 phosphorylation; correlates with increased microvessel density in patient tumors
23408	55808981	gtcagtgagg(T-G)aaaaaaaaat	(23408G) correlates with increased VEGFR2 mRNA in patient tumors

ATG = Position "1"

SNP in paranthesis

Localisation

Full length VEGFR2 is localized on the plasma membrane and is internalized in a VEGF binding-dependent manner (Koch S et al., 2012, Waltenberger J et al., 1994). Soluble VEGFR2 is secreted from the cell.

Function

VEGFR2 is the premier receptor mediating VEGF-A activity on endothelial cells, where it functions to enhance proliferation, migration, and survival (Gerber HP et al., 1998, Jia H et al., 2004, Terman BI et al., 1992, Waltenberger J et al., 1994). Vegfr2 also promotes the survival of hematopoietic stem cells (Larrivée B et al., 2003).

VEGFR2 is the principal VEGF receptor involved in vascular angiogenesis and the regulation of vascular permeability (Kowanz M et al., 2006, Terman BI et al., 1992). VEGFR2 activity on vascular endothelial cells in tumors promotes tumor angiogenesis (K. H. Plate et al., 1993, Millauer B et al., 1994). For the effects of VEGFR2 signaling on different cell types, see Table 2.

VEGF Signaling Inhibitors:

Strategies employed to target VEGF signaling are multifocal, consisting of monoclonal antibodies for both the ligands and VEGFRs, recombinant VEGFR extracellular domain fusion proteins (Table 3), and

small molecule receptor tyrosine kinase inhibitors (Table 4)

Mutations

Somatic

Increased VEGFR2 copy number has been identified in breast (Johansson I et al., 2012), non-small cell lung cancer (Yang F et al., 2011), and neurological malignancies (Blom T et al., 2010, Puputti M et al., 2006).

Missense mutations have been identified in hemangioma, leading to constitutive activation of VEGFR2 (Antonescu CR et al., 2009, Jinnin M et al., 2008, Walter JW et al., 2002). Wang et al., 2007, identified that polymorphisms in the VEGFR2 were associated with coronary heart disease (Wang Y et al., 2007) (Table 5).

Glubb et al., 2011, characterized the significance of selected single nucleotide polymorphisms on VEGFR2 function and expression (Table 6).

Of particular note, Glubb et al., 2011, identified that a SNP that results in the amino acid change Q472H, which was associated with increased VEGFR2 activity, and was correlated with increased microvessel density in non-small cell lung cancer patients (Glubb DM et al., 2011) (Table 6).

Table 7: Reports and Characterization of VEGFR2 Expression by Tumor Cells

Cancer Type	Reference(s)	Cancer Type	Reference(s)
Angiosarcoma	Antonescu et al., 2009	Melanoma	Straume et al., 2003
Bladder	Xia et al., 2006	Mesothelioma	Strizzi et al., 2001
Brain/Neurological	Knizetova et al., 2008; Nobusawa et al., 2011; Puputti et al., 2006; Yao et al., 2013; Blom et al., 2010	Multiple Myeloma	Giatromanolaki et al., 2010
Breast	Ghosh et al., 2008; Nakopoulou et al., 2002; Yan et al., 2015; Johansson et al., 2012	Myeloid Leukemia	Padró et al., 2002
Carcinoid	Silva et al., 2011	Ovarian	Spannuth et al., 2009; Chen et al., 2004
Cervical	Longatto-Filho et al., 2009	Pancreatic	Itakura et al., 2000; von Marschall et al., 2000; Chung et al., 2006
Colon	Takahashi et al., 1995, Giatromanolaki et al., 2007	Prostate	Köllermann et al., 2001; Jackson et al., 2002
Endometrial	Giatromanolaki et al., 2006	Renal Cell Carcinoma	Badalian et al., 2007
Esophageal	Gockel et al., 2008	Squamous (oral)	Sato et al., 2009
Gastric	Ozdemir et al., 2006	Thyroid	Rodríguez-Antona et al., 2010
Head and Neck	Lalla et al., 2003; Neuchrist et al., 2001	Lung	Carrillo de Santa Pau et al., 2009; Decaussin et al., 1999; Seto et al., 2006, Yang et al., 2011; Chatterjee et al., 2013

Implicated in

Various Cancers (see Table)

The expression VEGFR2 is increased by endothelial cells during tumor angiogenesis (K. H. Plate et al., 1993, Millauer B et al., 1994). VEGFR2 expression has also been identified on myeloid-derived suppressor cells, where it functions in splenic MDSC expansion and the chemotaxis of MDSCs into tumors (Dineen et al., 2008, Huang Y et al., 2007, Roland CL et al., 2009).

In addition to stromal cells, VEGFR2 expression by tumor cells has been identified in a variety of cancers, including bladder (Xia G et al., 2006), brain (Knizetova P et al., 2008, Nobusawa S1 et al., 2011, Puputti M et al., 2006, Yao X et al., 2013), breast (Ghosh S et al., 2008, Nakopoulou L et al., 2002, Yan JD et al., 2015), carcinoid (Silva SR et al., 2011), cervical (Longatto-Filho A et al., 2009), colon (Giatromanolaki A et al., 2007, Takahashi Y et al., 1995), endometrial ID: 5045> (Giatromanolaki A et al., 2006), esophageal (Gockel I et al., 2008), gastric (Ozdemir F et al., 2006), head

and neck (Lalla RV et al., 2003, Neuchrist C et al., 2001), lung (Carrillo de Santa Pau E et al., 2009, Chatterjee S et al., 2013, Decaussin M et al., 1999, Seto T et al., 2006, Yang F et al., 2011), melanoma (Straume O et al., 2003), mesothelioma (Strizzi L et al., 2001), multiple myeloma (Giatromanolaki A et al., 2010), myeloid leukemia (Padró T et al., 2002), ovarian (Chen H et al., 2004, Spannuth WA et al., 2009), pancreatic (Chung GG et al., 2006, Itakura J et al., 2000, von Marschall Z et al., 2000), prostate (Jackson MW et al., 2002, Köllermann J et al., 2001), renal cell carcinoma (Badalian G et al., 2007), squamous (Sato H et al., 2009), and thyroid (Rodríguez-Antona C et al., 2010), (Table 7).

In some cases, tumor cell expression of VEGFR2 appears to play an important function in tumor progression and correlates with worse prognosis. For example, Yang et al. (2011) identified VEGFR2 copy number gains (CNG) in 32% of tumors, which was associated with increased VEGFR2 protein, tumor angiogenesis, and correlated with poor prognosis (Yang F et al., 2011). Furthermore, Chatterjee et al. (2013) identified that the levels of VEGF/VEGFR2 binding on tumor cells strongly

correlated with tumor angiogenesis, and selective VEGFR2 inhibition had a significant combinatorial effect with MEK inhibitors in reducing tumor growth in preclinical models of NSCLC (Chatterjee S et al., 2013).

Yan et al. (2015) found that VEGFR2 expression by breast tumor cells was significantly correlated with increased lymph node metastasis, epithelial to mesenchymal transition (EMT) marker expression, and reduced overall survival (Yan JD et al., 2015).

For further review of expression and function of VEGFR2 in different cancers, see Table 7 and Goel and Mercurio, 2013 (Goel HL et al., 2013).

Coronary Heart Disease

Wang et al., 2007, identified that polymorphisms in the VEGFR2 were associated with coronary heart disease (Wang Y et al., 2007) (Table 5).

Hemangioma

Missense mutations have been identified in hemangioma, leading to constitutive activation of VEGFR2 (Antonescu CR et al., 2009, Jinnin M et al., 2008, Walter JW et al., 2002).

References

Achen MG, Jeltsch M, Kukk E, Mäkinen T, Vitali A, Wilks AF, Alitalo K, Stacker SA. Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4). *Proc Natl Acad Sci U S A*. 1998 Jan 20;95(2):548-53

Albuquerque RJ, Hayashi T, Cho WG, Kleinman ME, Dridi S, Takeda A, Baffi JZ, Yamada K, Kaneko H, Green MG, Chappell J, Wilting J, Weich HA, Yamagami S, Amano S, Mizuki N, Alexander JS, Peterson ML, Brekken RA, Hirashima M, Capoor S, Usui T, Ambati BK, Ambati J. Alternatively spliced vascular endothelial growth factor receptor-2 is an essential endogenous inhibitor of lymphatic vessel growth *Nat Med* 2009 Sep;15(9):1023-30

Antonescu CR, Yoshida A, Guo T, Chang NE, Zhang L, Agaram NP, Qin LX, Brennan MF, Singer S, Maki RG. KDR activating mutations in human angiosarcomas are sensitive to specific kinase inhibitors *Cancer Res* 2009 Sep 15;69(18):7175-9

Badalian G, Derecskei K, Szendroi A, Szendroi M, Tímá J. EGFR and VEGFR2 protein expressions in bone metastases of clear cell renal cancer *Anticancer Res* 2007 Mar-Apr;27(2):889-94

Blom T, Roselli A, Häyry V, Tynnenin O, Wartiovaara K, Korja M, Nordfors K, Haapasalo H, Nupponen NN. Amplification and overexpression of KIT, PDGFRA, and VEGFR2 in medulloblastomas and primitive neuroectodermal tumors *J Neurooncol* 2010 Apr;97(2):217-24

Carrillo de Santa Pau E, Arias FC, Caso Peláez E, Muñoz Molina GM, Sánchez Hernández I, Muguruza Trueba I, Moreno Balsalobre R, Sacristán López S, Gómez Pinillos A, del Val Toledo Lobo M. Prognostic significance of the expression of vascular endothelial growth factors A, B, C, and D and their receptors R1, R2, and R3 in patients with non-small cell lung cancer *Cancer* 2009 Apr 15;115(8):1701-12

Casella I, Feccia T, Chelucci C, Samoggia P, Castelli G, Guerriero R, Parolini I, Petrucci E, Pelosi E, Morsilli O, Gabbianelli M, Testa U, Peschle C. Autocrine-paracrine VEGF loops potentiate the maturation of megakaryocytic precursors through Flt1 receptor *Blood* 2003 Feb 15;101(4):1316-23

Chatterjee S, Heukamp LC, Siobal M, Schöttle J, Wiczorek C, Peifer M, Frasca D, Koker M, König K, Meder L, Rauh D, Buettner R, Wolf J, Brekken RA, Neumaier B, Christofori G, Thomas RK, Ullrich RT. Tumor VEGF:VEGFR2 autocrine feed-forward loop triggers angiogenesis in lung cancer *J Clin Invest* 2013 Apr;123(4):1732-40

Chen H, Ye D, Xie X, Chen B, Lu W. VEGF, VEGFRs expressions and activated STATs in ovarian epithelial carcinoma *Gynecol Oncol* 2004 Sep;94(3):630-5

Chung GG, Yoon HH, Zerkowski MP, Ghosh S, Thomas L, Harigopal M, Charette LA, Salem RR, Camp RL, Rimm DL, Burtness BA. Vascular endothelial growth factor, FLT-1, and FLK-1 analysis in a pancreatic cancer tissue microarray *Cancer* 2006 Apr 15;106(8):1677-84

Claesson-Welsh L, Welsh M. VEGFA and tumour angiogenesis *J Intern Med* 2013 Feb;273(2):114-27

Decaussin M, Sartelet H, Robert C, Moro D, Claraz C, Brambilla C, Brambilla E. Expression of vascular endothelial growth factor (VEGF) and its two receptors (VEGF-R1-Flt1 and VEGF-R2-Flk1/KDR) in non-small cell lung carcinomas (NSCLCs): correlation with angiogenesis and survival *J Pathol* 1999 Aug;188(4):369-77

Dineen SP, Lynn KD, Holloway SE, Miller AF, Sullivan JP, Shames DS, Beck AW, Barnett CC, Fleming JB, Brekken RA. Vascular endothelial growth factor receptor 2 mediates macrophage infiltration into orthotopic pancreatic tumors in mice *Cancer Res* 2008 Jun 1;68(11):4340-6

Elvert G, Kappel A, Heidenreich R, Englmeier U, Lanz S, Acker T, Rauter M, Plate K, Sieweke M, Breier G, Flamme I. Cooperative interaction of hypoxia-inducible factor-2alpha (HIF-2alpha) and Ets-1 in the transcriptional activation of vascular endothelial growth factor receptor-2 (Flk-1) *J Biol Chem* 2003 Feb 28;278(9):7520-30

Fuh G, Li B, Crowley C, Cunningham B, Wells JA. Requirements for binding and signaling of the kinase domain receptor for vascular endothelial growth factor *J Biol Chem* 1998 May 1;273(18):11197-204

Gerber HP, McMurtrey A, Kowalski J, Yan M, Keyt BA, Dixit V, Ferrara N. Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway Requirement for Flk-1/KDR activation *J Biol Chem*

Ghosh S, Sullivan CA, Zerkowski MP, Molinaro AM, Rimm DL, Camp RL, Chung GG. High levels of vascular endothelial growth factor and its receptors (VEGFR-1, VEGFR-2, neuropilin-1) are associated with worse outcome in breast cancer *Hum Pathol* 2008 Dec;39(12):1835-43

Giatromanolaki A, Bai M, Margaritis D, Bourantas KL, Koukourakis MI, Sivridis E, Gatter KC. Hypoxia and activated VEGF/receptor pathway in multiple myeloma *Anticancer Res* 2010 Jul;30(7):2831-6

Gille H, Kowalski J, Yu L, Chen H, Pisabarro MT, Davis-Smyth T, Ferrara N. A repressor sequence in the juxtamembrane domain of Flt-1 (VEGFR-1) constitutively inhibits vascular endothelial growth factor-dependent phosphatidylinositol 3'-kinase activation and endothelial cell migration *EMBO J* 2000 Aug 1;19(15):4064-73

- Glubb DM, Cerri E, Giese A, Zhang W, Mirza O, Thompson EE, Chen P, Das S, Jassem J, Rzyman W, Lingen MW, Salgia R, Hirsch FR, Dziadziuszko R, Ballmer-Hofer K, Innocenti F. Novel functional germline variants in the VEGF receptor 2 gene and their effect on gene expression and microvessel density in lung cancer Clin Cancer Res 2011 Aug 15;17(16):5257-67
- Gockel I, Moehler M, Frerichs K, Drescher D, Trinh TT, Duenschede F, Borschitz T, Schimanski K, Biesterfeld S, Herzer K, Galle PR, Lang H, Junginger T, Schimanski CC. Co-expression of receptor tyrosine kinases in esophageal adenocarcinoma and squamous cell cancer Oncol Rep 2008 Oct;20(4):845-50
- Goel HL, Mercurio AM. VEGF targets the tumour cell Nat Rev Cancer 2013 Dec;13(12):871-82
- Hervé MA, Meduri G, Petit FG, Domet TS, Lazennec G, Mourah S, Perrot-Appianat M. Regulation of the vascular endothelial growth factor (VEGF) receptor Flk-1/KDR by estradiol through VEGF in uterus J Endocrinol 2006 Jan;188(1):91-9
- Huang Y, Chen X, Dikov MM, Novitskiy SV, Mosse CA, Yang L, Carbone DP. Distinct roles of VEGFR-1 and VEGFR-2 in the aberrant hematopoiesis associated with elevated levels of VEGF Blood 2007 Jul 15;110(2):624-31
- Itakura J, Ishiwata T, Shen B, Kornmann M, Korc M. Concomitant over-expression of vascular endothelial growth factor and its receptors in pancreatic cancer Int J Cancer 2000 Jan 1;85(1):27-34
- Jackson MW, Roberts JS, Heckford SE, Ricciardelli C, Stahl J, Choong C, Horsfall DJ, Tilley WD. A potential autocrine role for vascular endothelial growth factor in prostate cancer Cancer Res 2002 Feb 1;62(3):854-9
- Jia H, Bagherzadeh A, Bicknell R, Duchon MR, Liu D, Zachary I. Vascular endothelial growth factor (VEGF)-D and VEGF-A differentially regulate KDR-mediated signaling and biological function in vascular endothelial cells J Biol Chem 2004 Aug 20;279(34):36148-57
- Jinnin M, Medici D, Park L, Limaye N, Liu Y, Boscolo E, Bischoff J, Vikkula M, Boye E, Olsen BR. Suppressed NFAT-dependent VEGFR1 expression and constitutive VEGFR2 signaling in infantile hemangioma Nat Med 2008 Nov;14(11):1236-46
- Johansson I, Aaltonen KE, Ebbesson A, Grabau D, Wigerup C, Hedenfalk I, Rydén L. Increased gene copy number of KIT and VEGFR2 at 4q12 in primary breast cancer is related to an aggressive phenotype and impaired prognosis Genes Chromosomes Cancer 2012 Apr;51(4):375-83
- Joukov V, Pajusola K, Kaipainen A, Chilov D, Lahtinen I, Kukk E, Saksela O, Kalkkinen N, Alitalo K. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases EMBO J 1996 Jan 15;15(2):290-98
- Köllermann J, Helpap B. Expression of vascular endothelial growth factor (VEGF) and VEGF receptor Flk-1 in benign, premalignant, and malignant prostate tissue Am J Clin Pathol 2001 Jul;116(1):115-21
- Kappel A, Schlaeger TM, Flamme I, Orkin SH, Risau W, Breier G. Role of SCL/Tal-1, GATA, and ets transcription factor binding sites for the regulation of flk-1 expression during murine vascular development Blood 2000 Nov 1;96(9):3078-85
- Katoh O, Tauchi H, Kawaiishi K, Kimura A, Satow Y. Expression of the vascular endothelial growth factor (VEGF) receptor gene, KDR, in hematopoietic cells and inhibitory effect of VEGF on apoptotic cell death caused by ionizing radiation Cancer Res 1995 Dec 1;55(23):5687-92
- Kendall RL, Rutledge RZ, Mao X, Tebben AJ, Hungate RW, Thomas KA. Vascular endothelial growth factor receptor KDR tyrosine kinase activity is increased by autophosphorylation of two activation loop tyrosine residues J Biol Chem 1999 Mar 5;274(10):6453-60
- Kim JY, Lee RH, Kim TM, Kim DW, Jeon YJ, Huh SH, Oh SY, Kyba M, Kataoka H, Choi K, Ornitz DM, Chae JI, Park C. OVOL2 is a critical regulator of ER71/ETV2 in generating FLK1+, hematopoietic, and endothelial cells from embryonic stem cells Blood 2014 Nov 6;124(19):2948-52
- Knizetova P, Ehrmann J, Hlobilkova A, Vancova I, Kalita O, Kolar Z, Bartek J. Autocrine regulation of glioblastoma cell cycle progression, viability and radioresistance through the VEGF-VEGFR2 (KDR) interplay Cell Cycle 2008 Aug 15;7(16):2553-61
- Koch S, Claesson-Welsh L. Signal transduction by vascular endothelial growth factor receptors Cold Spring Harb Perspect Med 2012 Jul;2(7):a006502
- Kowanetz M, Ferrara N. Vascular endothelial growth factor signaling pathways: therapeutic perspective Clin Cancer Res 2006 Sep 1;12(17):5018-22
- Lalla RV, Boisonneau DS, Spiro JD, Kreutzer DL. Expression of vascular endothelial growth factor receptors on tumor cells in head and neck squamous cell carcinoma Arch Otolaryngol Head Neck Surg 2003 Aug;129(8):882-8
- Larrivée B, Lane DR, Pollet I, Olive PL, Humphries RK, Karsan A. Vascular endothelial growth factor receptor-2 induces survival of hematopoietic progenitor cells J Biol Chem 2003 Jun 13;278(24):22006-13
- Lee D, Park C, Lee H, Lugus JJ, Kim SH, Arentson E, Chung YS, Gomez G, Kyba M, Lin S, Janknecht R, Lim DS, Choi K. ER71 acts downstream of BMP, Notch, and Wnt signaling in blood and vessel progenitor specification Cell Stem Cell 2008 May 8;2(5):497-507
- Longatto-Filho A, Pinheiro C, Martinho O, Moreira MA, Ribeiro LF, Queiroz GS, Schmitt FC, Baltazar F, Reis RM. Molecular characterization of EGFR, PDGFRA and VEGFR2 in cervical adenocarcinoma BMC Cancer 2009 Jun 29;9:212
- Matthews W, Jordan CT, Gavin M, Jenkins NA, Copeland NG, Lemischka IR. A receptor tyrosine kinase cDNA isolated from a population of enriched primitive hematopoietic cells and exhibiting close genetic linkage to c-kit Proc Natl Acad Sci U S A 1991 Oct 15;88(20):9026-30
- Meyer M, Clauss M, Lepple-Wienhues A, Waltenberger J, Augustin HG, Ziche M, Lanz C, Büttner M, Rziha HJ, Dehio C. A novel vascular endothelial growth factor encoded by Orf virus, VEGF-E, mediates angiogenesis via signalling through VEGFR-2 (KDR) but not VEGFR-1 (Flt-1) receptor tyrosine kinases EMBO J 1999 Jan 15;18(2):363-74
- Millauer B, Shawver LK, Plate KH, Risau W, Ullrich A. Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant Nature 1994 Feb 10;367(6463):576-9
- Murakami M, Nguyen LT, Hatanaka K, Schachterle W, Chen PY, Zhuang ZW, Black BL, Simons M. FGF-dependent regulation of VEGF receptor 2 expression in mice J Clin Invest 2011 Jul;121(7):2668-78
- Nakopoulou L, Stefanaki K, Panayotopoulou E, Giannopoulou I, Athanassiadou P, Gakiopoulou-Givalou H, Louvrou A. Expression of the vascular endothelial growth

- factor receptor-2/Flk-1 in breast carcinomas: correlation with proliferation *Hum Pathol* 2002 Sep;33(9):863-70
- Neuchrist C, Erovic BM, Handisurya A, Steiner GE, Rockwell P, Gedlicka C, Burian M. Vascular endothelial growth factor receptor 2 (VEGFR2) expression in squamous cell carcinomas of the head and neck *Laryngoscope* 2001 Oct;111(10):1834-41
- Nobusawa S, Stawski R, Kim YH, Nakazato Y, Ohgaki H. Amplification of the PDGFRA, KIT and KDR genes in glioblastoma: a population-based study *Neuropathology* 2011 Dec;31(6):583-8
- Oelrichs RB, Reid HH, Bernard O, Ziemiecki A, Wilks AF. NYK/FLK-1: a putative receptor protein tyrosine kinase isolated from E10 embryonic neuroepithelium is expressed in endothelial cells of the developing embryo *Oncogene* 1993 Jan;8(1):11-8
- Ogawa S, Oku A, Sawano A, Yamaguchi S, Yazaki Y, Shibuya M. A novel type of vascular endothelial growth factor, VEGF-E (NZ-7 VEGF), preferentially utilizes KDR/Flk-1 receptor and carries a potent mitotic activity without heparin-binding domain *J Biol Chem* 1998 Nov 20;273(47):31273-82
- Ozdemir F, Akdogan R, Aydin F, Reis A, Kavgaci H, Gul S, Akdogan E. The effects of VEGF and VEGFR-2 on survival in patients with gastric cancer *J Exp Clin Cancer Res* 2006 Mar;25(1):83-8
- Padró T, Bieker R, Ruiz S, Steins M, Retzlaff S, Bürger H, Büchner T, Kessler T, Herrera F, Kienast J, Müller-Tidow C, Serve H, Berdel WE, Mesters RM. Overexpression of vascular endothelial growth factor (VEGF) and its cellular receptor KDR (VEGFR-2) in the bone marrow of patients with acute myeloid leukemia *Leukemia* 2002 Jul;16(7):1302-10
- Plate KH, Breier G, Millauer B, Ullrich A, Risau W. Up-regulation of vascular endothelial growth factor and its cognate receptors in a rat glioma model of tumor angiogenesis *Cancer Res* 1993 Dec 1;53(23):5822-7
- Puputti M, Tynninén O, Sihto H, Blom T, Mäenpää H, Isola J, Paetau A, Joensuu H, Nupponen NN. Amplification of KIT, PDGFRA, VEGFR2, and EGFR in gliomas *Mol Cancer Res* 2006 Dec;4(12):927-34
- Rodríguez-Antona C, Pallares J, Montero-Conde C, Inglada-Pérez L, Castelblanco E, Landa I, Leskelä S, Leandro-García LJ, López-Jiménez E, Letón R, Cascón A, Lerma E, Martín MC, Carralero MC, Mauricio D, Cigudosa JC, Matias-Guiu X, Robledo M. Overexpression and activation of EGFR and VEGFR2 in medullary thyroid carcinomas is related to metastasis *Endocr Relat Cancer* 2010 Jan 29;17(1):7-16
- Roland CL, Dineen SP, Lynn KD, Sullivan LA, Dellinger MT, Sadegh L, Sullivan JP, Shames DS, Brekken RA. Inhibition of vascular endothelial growth factor reduces angiogenesis and modulates immune cell infiltration of orthotopic breast cancer xenografts *Mol Cancer Ther* 2009 Jul;8(7):1761-71
- Sato H, Takeda Y. VEGFR2 expression and relationship between tumor neovascularization and histologic characteristics in oral squamous cell carcinoma *J Oral Sci* 2009 Dec;51(4):551-7
- Seto T, Higashiyama M, Funai H, Imamura F, Uematsu K, Seki N, Eguchi K, Yamanaka T, Ichinose Y. Prognostic value of expression of vascular endothelial growth factor and its flt-1 and KDR receptors in stage I non-small-cell lung cancer *Lung Cancer* 2006 Jul;53(1):91-6
- Shalaby F, Rossant J, Yamaguchi TP, Gertsenstein M, Wu XF, Breitman ML, Schuh AC. Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice *Nature* 1995 Jul 6;376(6535):62-6
- Shinkai A, Ito M, Anazawa H, Yamaguchi S, Shitara K, Shibuya M. Mapping of the sites involved in ligand association and dissociation at the extracellular domain of the kinase insert domain-containing receptor for vascular endothelial growth factor *J Biol Chem* 1998 Nov 20;273(47):31283-8
- Silva SR, Bowen KA, Rychahou PG, Jackson LN, Weiss HL, Lee EY, Townsend CM Jr, Evers BM. VEGFR-2 expression in carcinoid cancer cells and its role in tumor growth and metastasis *Int J Cancer* 2011 Mar 1;128(5):1045-56
- Solowiej J, Bergqvist S, McTigue MA, Marrone T, Quenzer T, Cobbs M, Ryan K, Kania RS, Diehl W, Murray BW. Characterizing the effects of the juxtamembrane domain on vascular endothelial growth factor receptor-2 enzymatic activity, autophosphorylation, and inhibition by axitinib *Biochemistry* 2009 Jul 28;48(29):7019-31
- Spannuth WA, Nick AM, Jennings NB, Armaiz-Pena GN, Mangala LS, Danes CG, Lin YG, Merritt WM, Thaker PH, Kamat AA, Han LY, Tonra JR, Coleman RL, Ellis LM, Sood AK. Functional significance of VEGFR-2 on ovarian cancer cells *Int J Cancer* 2009 Mar 1;124(5):1045-53
- Straume O, Akslen LA. Increased expression of VEGF-receptors (FLT-1, KDR, NRP-1) and thrombospondin-1 is associated with glomeruloid microvascular proliferation, an aggressive angiogenic phenotype, in malignant melanoma *Angiogenesis* 2003;6(4):295-301
- Strizzi L, Catalano A, Vianale G, Orecchia S, Casalini A, Tassi G, Puntoni R, Mutti L, Procopio A. Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma *J Pathol* 2001 Apr;193(4):468-75
- Takahashi Y, Kitadai Y, Bucana CD, Cleary KR, Ellis LM. Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer *Cancer Res* 1995 Sep 15;55(18):3964-8
- Terman BI, Carrion ME, Kovacs E, Rasmussen BA, Eddy RL, Shows TB. Identification of a new endothelial cell growth factor receptor tyrosine kinase *Oncogene* 1991 Sep;6(9):1677-83
- Terman BI, Dougher-Vermazen M, Carrion ME, Dimitrov D, Armellino DC, Gospodarowicz D, Böhlen P. Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor *Biochem Biophys Res Commun* 1992 Sep 30;187(3):1579-86
- Terman BI, Jani-Sait S, Carrion ME, Shows TB. The KDR gene maps to human chromosome 4q31.2-q32, a locus which is distinct from locations for other type III growth factor receptor tyrosine kinases *Cytogenet Cell Genet*
- Waltenberger J, Claesson-Welsh L, Siegbahn A, Shibuya M, Heldin CH. Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor *J Biol Chem* 1994 Oct 28;269(43):26988-95
- Walter JW, North PE, Waner M, Mizeracki A, Blei F, Walker JW, Reinisch JF, Marchuk DA. Somatic mutation of vascular endothelial growth factor receptors in juvenile hemangioma *Genes Chromosomes Cancer* 2002 Mar;33(3):295-303
- Wang Y, Zheng Y, Zhang W, Yu H, Lou K, Zhang Y, Qin Q, Zhao B, Yang Y, Hui R. Polymorphisms of KDR gene are associated with coronary heart disease *J Am Coll Cardiol* 2007 Aug 21;50(8):760-7

Xia G, Kumar SR, Hawes D, Cai J, Hassanieh L, Groshen S, Zhu S, Masood R, Quinn DI, Broek D, Stein JP, Gill PS. Expression and significance of vascular endothelial growth factor receptor 2 in bladder cancer J Urol 2006 Apr;175(4):1245-52

Yan JD, Liu Y, Zhang ZY, Liu GY, Xu JH, Liu LY, Hu YM. Expression and prognostic significance of VEGFR-2 in breast cancer Pathol Res Pract 2015 Jul;211(7):539-43

Yang F, Tang X, Riquelme E, Behrens C, Nilsson MB, Giri U, Varella-Garcia M, Byers LA, Lin HY, Wang J, Raso MG, Girard L, Coombes K, Lee JJ, Herbst RS, Minna JD, Heymach JV, Wistuba II. Increased VEGFR-2 gene copy is associated with chemoresistance and shorter survival in

patients with non-small-cell lung carcinoma who receive adjuvant chemotherapy Cancer Res 2011 Aug 15;71(16):5512-21

Yao X, Ping Y, Liu Y, Chen K, Yoshimura T, Liu M, Gong W, Chen C, Niu Q, Guo D, Zhang X, Wang JM, Bian X. Vascular endothelial growth factor receptor 2 (VEGFR-2) plays a key role in vasculogenic mimicry formation, neovascularization and tumor initiation by Glioma stem-like cells PLoS One 2013;8(3):e57188

von Marschall Z, Cramer T, Höcker M, Burde R, Plath T, Schirner M, Heidenreich R, Breier G, Riecken EO, Wiedenmann B, Rosewicz S. De novo expression of vascular endothelial growth factor in human pancreatic cancer: evidence for an autocrine mitogenic loop Gastroenterology 2000 Nov;119(5):1358-72

This article should be referenced as such:

Sorrelle N, Brekken R. KDR (kinase insert domain receptor)/Vascular Endothelial Growth Factor Receptor 2 (VEGFR2). Atlas Genet Cytogenet Oncol Haematol. 2016; 20(7):392-402.
